Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration

Gut

Volumn 39, Issue 1, 1996, Pages 63-68

  Van Os, E C ^a   Zins, B J ^a   Sandborn, W J ^a   Mays, D C ^a   Tremaine, W J ^a   Mahoney, D W ^a   Zinsmeister, A R ^a   Lipsky, J J ^a  

^a MAYO CLINIC   (United States)

Author keywords

6 mercaptopurine; azathioprine; Crohn's disease; inflammatory bowel disease; pharmacokinetics; ulcerative colitis

Indexed keywords

AZATHIOPRINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; ENTERITIS; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION;

EID: 0029975534     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.39.1.63     Document Type: Article

References (36)

1. Willoughby JMT, Kumar PJ, Beckett J, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; ii: 944-7.
2. Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Dig Dis 1975; 20: 721-6.
3. O'Donoghue DP, Dawson AM, Powell-Tuck J, Bown RL, Lennard-Jones JE. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; ii: 955-7.
4. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine, a long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-7.
5. Ewe K, Press AF, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisone in active Crohn's disease. Gastroenterology 1993; 105: 367-72.
6. Candy S, Wright JP, Gerber M, Adams G, Gerig M, Goodman R. A controlled double-blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8.
7. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995; 122: 132-42.
8. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on a controlled therapeutic trial. BMJ 1974; 4: 627-39.
9. Caprilli R, Carratu R, Babbini M. A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. A preliminary report. Dig Dis 1975; 20: 115-20.
10. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975; 69: 96-9.
11. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. BMJ 1982; 284: 1291-2.
12. Hawthorne AB, Logan RFA, Hawkey CJ, Foster PN, Axon ATR, Swarbrick ET, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 20-2.
13. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
14. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years experience. Gut 1993; 34: 1081-5.
15. Sutherland LR. Topical treatment of ulcerative colitis. Med Clin North Am 1990; 74: 119-31.
16. Chalmers AH. Studies on the mechanism of formation of 5-mercapto-1-methyl-4-nitroimidazole. A metabolite of the immunosuppressive drug azathioprine. Biochem Pharmacol 1974; 23: 1891-901.
17. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-39.
18. Weinshilboum RM. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 1992; 22: 1055-71.
19. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54.
20. Zimm S, Ettinger LJ, Holcenberg JS, Kamen BA, Vietti TJ, Belasco J, et al. Phase 1 and clinical pharmacological study of mercaptopurine administered as a prolonged infusion. Cancer Res 1985; 45: 1869-73.
21. Van Os EC, McKinney JA, Zins BJ, Mays DC, Schriver Z, Sandborn WJ, et al. Simultaneous determination of azathioprine and 6-mercaptopurine by high performance liquid chromatography. Journal of Chromatography B: Biomedical applications (in press).
22. Lilliemark J, Pettersson B, Lafolie P, Zweig T, Peterson C. Determination of plasma azathioprine and 6-mercaptopurine in patients with rheumatoid arthritis treated with oral azathioprine. Ther Drug Monit 1990; 12: 339-43.
23. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625-9.
24. Rowland M, Tozer TN. Clinical pharmacokinetics. 2nd ed. Philadelphia, PA: Lea & Febiger, 1989.
25. Odlind B, Hartvig P, Linström B, Lönnerholm GL, Tufveson G, Grefberg N. Serum azathioprine and 6-mercaptopurine levels in immunosuppressive activity after azathioprine in uremic patients. Int J Immunopharmacol 1986; 8: 1-11.
26. Zimm S, Collins JM, Riccardi R, O'Neill D, Narang PK, Chabner B, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 1983; 308: 1005-9.
27. Rectal topical corticosteroid preparations. Drug Ther Bull 1991; 29: 66-8.
28. Kato Y, Matsushita T, Yokoyama T, Mohri K. Enhanced bioavailability of 6-mercaptopurine after rectal administration in rats. Pharm Res 1992; 9: 697-9.
29. Kato Y, Matsushita T, Uchida H, Yokoyama T, Mohri K. Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of 'first-pass' metabolism. Eur J Clin Pharmacol 1992; 42: 619-22.
30. Bondesen S, Brønnum Schou J, Pedersen V, Rafiolsadat Z, Honoré Hansen S, Hvidberg EF. Absorption of 5-aminosalicylic acid from colon and rectum. Br J Clin Pharmacol 1988; 25: 269-72.
31. Norlander B, Gotthard R, Ström M. Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers. Aliment Pharmacol Therap 1990; 4: 497-505.
32. Norlander B, Gotthard R, Ström M. Steady-state pharmacokinetics of enteric coated 5-amino-salicylic acid tablets in healthy volunteers and in patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Therap 1991; 5: 291-300.
33. DeLeve LD, Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther 1991; 52: 287-305.
34. Bostrom B, Erdmann G. Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 1993; 15: 80-6.
35. Gruber SA. Locoregional immunosuppression of organ transplants. Immunol Rev 1992; 129: 5-30.
36. Gruber SA, Hrushesky WJM, Cipolle RJ, Erdmann GR, Burke BA, Skjei KL, et al. Local immunosuppression with reduced systemic toxicity in a canine renal allograft model. Transplantation 1989; 48: 936-43.